Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Prescient Therapeutics Limited ( (AU:PTX) ) is now available.
Prescient Therapeutics Limited has announced a proposed issue of 74,462,500 ordinary fully paid securities, with the issuance date set for August 8, 2025. This move is part of a placement or other type of issue, which could potentially enhance the company’s financial position and support its ongoing projects in the biotechnology sector.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on the development of targeted therapies for cancer treatment. The company is engaged in advancing its pipeline of oncology products aimed at improving patient outcomes in the cancer treatment market.
Average Trading Volume: 1,111,541
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$36.24M
For an in-depth examination of PTX stock, go to TipRanks’ Overview page.